Replies to post #99985 on Biotech Values

[DewDiligence]

The virologic-failure rate difference was higher in ECHO trial (11.0% vs 4.4%) than in THRIVE (7.1% vs 5.3%), and there's no explanation for this either.

The disparity between the VF deltas of the two trials wasn’t statsig, as far as I know. It looks like routine statistical noise.